Home - AME Clinical Trials Review

Interviews with Outstanding Authors (2024)

In 2024, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

ACTR Annual Report 2024

Greetings from the Editorial Office of AME Clinical Trials Review (ACTR).

We are glad to present the 2024 Annual Report of ACTR, which has shown the author statistics, pageviews and visits of ACTR articles, as well as previews of upcoming reviews and commentaries in the coming year.

Prediction of lymphatic invasion for patients with early gastric cancer: a review

Elfriede Bollschweiler, Patrick S. Plum
Review Article｜25 August 2024
doi: 10.21037/actr-24-33

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

I am excited to announce the launch of AME Clinical Trials Review (ACTR), an open-access, peer-reviewed journal publishing commentaries on clinical trials in all phases.

Why launch ACTR? Tens of thousands of clinical trials are published every year, and the total number of published clinical trials in PubMed is nearly a million, with an additional 80,000 recruiting and not-yet-recruiting studies registered in the ClinicalTrials.gov platform.

Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review

Eric M. Robinson, Raja Flores, Brian Housman
Review Article｜25 December 2024
doi: 10.21037/actr-24-149

‹ ›

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: actr@amegroups.com
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Review Article

Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review

Eric M. Robinson, Raja Flores, Brian Housman

AME Clinical Trials Review

2024;

112

(25 December 2024)

PDF Full Text (107) Reporting Checklist Peer Review File COI Form Open Access

Editorial Commentary

Less radiation, same bang, fewer bucks?

Scott I. Reznik, John Keene Waters

AME Clinical Trials Review

2024;

111

(25 December 2024)

PDF Full Text (45) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial

Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group

AME Clinical Trials Review

2024;

110

(25 December 2024)

PDF Full Text (145) Peer Review File COI Form Open Access

Editorial Commentary

Need of the hour—advancements in treatment of pancreatic cancer

Priyadarshini Pathak, Colin Weekes

AME Clinical Trials Review

2024;

109

(25 December 2024)

PDF Full Text (58) Peer Review File COI Form Open Access

Editorial Commentary

Combining [¹⁷⁷Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now

Miguel Muniz, Daniel S. Childs, Oliver Sartor

AME Clinical Trials Review

2024;

108

(25 December 2024)

PDF Full Text (72) Peer Review File COI Form Open Access

Editorial Commentary

Tislelizumab in hepatocellular carcinoma: a duet or a solo performance?

Claudia Campani, Elisa Pellegrini, Fabio Marra

AME Clinical Trials Review

2024;

107

(25 December 2024)

PDF Full Text (60) Peer Review File COI Form Open Access

Editorial Commentary

To fast or not to fast—that is the question?

Vinay Goel, Nitesh Nerlekar, Adam J. Brown

AME Clinical Trials Review

2024;

106

(25 December 2024)

PDF Full Text (59) Peer Review File COI Form Open Access

Editorial Commentary

The COMBAT trial: use of bipolar androgen therapy to enhance immune checkpoint blockade in the management of metastatic castration-resistant prostate cancer

Harshraj Leuva, Benjamin A. Teply

AME Clinical Trials Review

2024;

105

(25 December 2024)

PDF Full Text (56) Peer Review File COI Form Open Access

Editorial Commentary

Novel agents in acute lymphoblastic leukemia: an expanding role for inotuzumab ozogamicin in patients with measurable residual disease

Massimiliano Bonifacio

AME Clinical Trials Review

2024;

104

(25 December 2024)

PDF Full Text (44) Peer Review File COI Form Open Access

Editorial Commentary

Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration

Lokeswara Rao Sajja, Pradeep Narayan, Sanjeeth Peter

AME Clinical Trials Review

2024;

103

(25 December 2024)

PDF Full Text (68) Peer Review File COI Form Open Access

Editorial Commentary

Comparison of drug-eluting bead transcatheter arterial chemoembolization (TACE) versus conventional TACE for hepatocellular carcinoma with portal vein thrombus

Paschalis Gavriilidis, Timothy M. Pawlik

AME Clinical Trials Review

2024;

102

(25 December 2024)

PDF Full Text (41) Peer Review File COI Form Open Access

Editorial Commentary

FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer

Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka

AME Clinical Trials Review

2024;

101

(25 December 2024)

PDF Full Text (70) Peer Review File COI Form Open Access

Editorial Commentary

Antiplatelet therapy after coronary artery bypass surgery: the results from the randomized DACAB trial

Paolo Nardi, Augusto D’Onofrio

AME Clinical Trials Review

2024;

100

(25 December 2024)

PDF Full Text (37) Peer Review File COI Form Open Access

Editorial Commentary

What is the optimal therapeutic option for patients diagnosed with hormone receptor-positive, HER2-negative breast cancer in visceral crisis?—insights from the RIGHT CHOICE trial

Alexandre Xu-Vuillard, Thomas Grinda

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (80) Peer Review File COI Form Open Access

Editorial Commentary

Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment

Fiona Britton, Igor Gomez-Randulfe, Loredana Mrak, Raffaele Califano

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (47) Peer Review File COI Form Open Access

Editorial Commentary

The significance of local intervention for oligometastatic esophageal squamous cell carcinoma

Masanobu Nakajima, Kazuyuki Kojima

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (40) Peer Review File COI Form Open Access

Editorial Commentary

From lifelong therapy to intermittent treatment: the future of chronic myeloid leukemia management—commentary on interim results from DAstop2 trial

Tomáš Horňák, Daniela Žáčková

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (57) Peer Review File COI Form Open Access

Editorial Commentary

Drug-coated ballons finally land in the United States: an appraisal of the agent IDE randomized clinical trial

Filippo Luca Gurgoglione, Bernardo Cortese

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (47) Peer Review File COI Form Open Access

Editorial Commentary

Review on LAURA: is it a game changer for unresectable stage III EGFR-mutated non-small-cell lung cancer?

Koichiro Nozaki, Satoshi Watanabe, Toshiaki Kikuchi

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (76) Peer Review File COI Form Open Access

Editorial Commentary

Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?

Valérie Fonteyne, Flor Verghote, Camille Berquin, Daan De Maeseneer, Geert Villeirs, Kathia De Man

AME Clinical Trials Review

2024;

(25 December 2024)

PDF Full Text (50) Peer Review File COI Form Open Access

View more articles

Currently no content available!

Editorial Commentary

What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?

Toyoaki Hida

Published online: 20 October 2023

PDF Full Text (3004) Peer Review File COI Form Open Access

Editorial Commentary

The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer

Antonio Rossi, Ettore Mari, Domenico Galetta

Published online: 06 September 2023

PDF Full Text (2757) Peer Review File COI Form Open Access

Editorial Commentary

Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer

Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu

Published online: 15 August 2024

PDF Full Text (1524) Peer Review File COI Form Open Access

Editorial Commentary

The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)

Yuji Uehara, Aaron C. Tan

Published online: 06 June 2024

PDF Full Text (1151) Peer Review File COI Form Open Access

Editorial Commentary

ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma

Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona

Published online: 09 April 2024

PDF Full Text (1043) Peer Review File COI Form Open Access

Editorial Commentary

KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction

Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo

Published online: 11 June 2024

PDF Full Text (872) Peer Review File COI Form Open Access

Editorial Commentary

The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer

Igor Gómez-Randulfe, Raffaele Califano

Published online: 24 November 2023

PDF Full Text (821) Peer Review File COI Form Open Access

Editorial Commentary

Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?

Noemi Maria Giorgiano, Francesca Pentimalli, Giovanni Natale, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli

Published online: 02 February 2024

PDF Full Text (841) Peer Review File COI Form Open Access

Editorial Commentary

Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri

Published online: 09 April 2024

PDF Full Text (811) Peer Review File COI Form Open Access

Editorial

Advancing the understanding, reflection, and translation of clinical trials: inaugural editorial to AME Clinical Trials Review

Kaiping Zhang

Published online: 31 May 2023

PDF Full Text (705) COI Form Open Access

Editorial Commentary

Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?

Daniela Damiani, Mario Tiribelli

Published online: 20 June 2024

PDF Full Text (691) Peer Review File COI Form Open Access

Editorial Commentary

EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges

Mingjia Li, Dwight H. Owen, Gregory A. Otterson

Published online: 18 December 2023

PDF Full Text (653) Peer Review File COI Form Open Access

Editorial Commentary

Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer

Lauren Tagliaferro Epler, Joel W. Neal

Published online: 29 January 2024

PDF Full Text (673) Peer Review File COI Form Open Access

Editorial Commentary

Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma

Shinji Yuhara, Yoshihisa Shimada, Masaaki Sato

Published online: 27 March 2024

PDF Full Text (611) Peer Review File COI Form Open Access

Editorial Commentary

Hyperthermic intraperitoneal chemotherapy in colorectal cancer: is COLOPEC just another brick in the wall?

Beate Rau, Sebastian Stintzing

Published online: 18 June 2024

PDF Full Text (629) Peer Review File COI Form Open Access

Editorial Commentary

Targeting TIGIT in lung cancer: will it stick to the wall?

Jiaxin Niu, Saba Radhi

Published online: 21 June 2024

PDF Full Text (625) Peer Review File COI Form Open Access

Editorial Commentary

The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC

Takahiro Karasaki

Published online: 01 February 2024

PDF Full Text (516) Peer Review File COI Form Open Access

Editorial Commentary

YK-029A in the landscape of treatments for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations

Margaret Locke, Wint Yan Aung, Nagashree Seetharamu

Published online: 20 June 2024

PDF Full Text (566) Peer Review File COI Form Open Access

Editorial Commentary

Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?

Yu Saida, Satoshi Watanabe, Toshiaki Kikuchi

Published online: 17 June 2024

PDF Full Text (534) Peer Review File COI Form Open Access

Editorial Commentary

The future of EGFR exon 20 targeting in non-small cell lung cancer

Petros Christopoulos

Published online: 13 June 2024

PDF Full Text (507) Peer Review File COI Form Open Access

Full Most Read article list >>

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Publishing Information

AME Clinical Trials Review is published by AME Publishing Company

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Contact us

General editorial enquiries:

Copyright related contact:

Commercial Sales contact (Reprints, advertising, etc.):

Publishing Information

Social Media